Estradiol III; Elecsys and cobas e analyzers; REF 06656021 190; M 6.5 mL, R1 9 mL, R2 9 mL, Fo...

FDA Device Recall #Z-1276-2016 — Class II — March 7, 2016

Recall Summary

Recall Number Z-1276-2016
Classification Class II — Moderate risk
Date Initiated March 7, 2016
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Roche Diagnostics Operations, Inc.
Location Indianapolis, IN
Product Type Devices
Quantity 23,630

Product Description

Estradiol III; Elecsys and cobas e analyzers; REF 06656021 190; M 6.5 mL, R1 9 mL, R2 9 mL, For USA: CONTENT M Streptavidin-coated microparticles 0.72 mg/ml; R1 Two biotinylated monoclonal anti-estradiol antibodies (rabbit) 2.5 ng/m and 4.5 ng/mL Mesterolone 130 ng/mL; R2 Estradiol derivative, labeled with ruthenium complex 4.5 ng/mL; Rx only Product Usage: Immunoassay for the in vitro quantitative determination of estradiol in human serum and plasma. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers.

Reason for Recall

Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e

Distribution Pattern

US Nationwide Distribution including Puerto Rico.

Lot / Code Information

Elecsys Estradiol III: 06656021190; all lot numbers are affected.

Other Recalls from Roche Diagnostics Operations, Inc.

Recall # Classification Product Date
Z-1476-2026 Class II cobas pro integrated solutions with cobas c 503... Jan 20, 2026
Z-1009-2026 Class II The Elecsys Anti-TSHR immunoassay is a three-st... Nov 21, 2025
Z-0489-2025 Class II cobas HCYS, Homocysteine Enzymatic Assay, Mater... Oct 17, 2024
Z-3187-2024 Class II Creatine Kinase (CK) used on cobas c 311/501/50... Aug 15, 2024
Z-0352-2024 Class II Tina-quant D-Dimer Test System, Fibrinogen/Fibr... Oct 3, 2023

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.